ProfileGDS5678 / 1449740_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 52% 51% 51% 54% 50% 53% 58% 74% 75% 54% 51% 60% 51% 51% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3277652
GSM967853U87-EV human glioblastoma xenograft - Control 23.225351
GSM967854U87-EV human glioblastoma xenograft - Control 33.2279451
GSM967855U87-EV human glioblastoma xenograft - Control 43.2628254
GSM967856U87-EV human glioblastoma xenograft - Control 53.1396450
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.383353
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5985258
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8877874
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0181175
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3185154
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2136151
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5517560
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2383451
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2181351